Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Telehealth company Hims Hers is pushing the boundaries of drug compounding and testing the limits of regulators.

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Telehealth provider Hims & Hers Health is defending its planned Super Bowl ad, which is styled as a political manifesto ...

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - February 6, 2025) - Novo Nordisk A/S (NYSE: ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...

Trump's threat of imposing a tariff on Denmark over desires to acquire Greenland has caught the attention of one of the ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...